Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industrly on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets in coming years.

You may also be interested in...



Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 2 of 2)

Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industry on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets. In part one of this interview, Kley discussed challenges facing the industry and the role that emerging markets can play. In this second part, he discusses Merck KGaA's pipeline and how the company is positioning itself on the global stage.

Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 2 of 2)

Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industry on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets. In part one of this interview, Kley discussed challenges facing the industry and the role that emerging markets can play. In this second part, he discusses Merck KGaA's pipeline and how the company is positioning itself on the global stage.

Merck Serono Opens Bioanalysis Center In Beijing To Support Clinical Trials In Asia; Plans To Double Staff

SHANGHAI - Merck KGaA's biopharmaceutical arm Merck Serono SA opened Aug. 31 a new R&D laboratory in Beijing to establish bioanalysis capability that will support clinical trials in Asia. The site is on Chinese contract research organization Pharmaron's new campus in the Beijing Economic and Technological Development Area

Related Content

UsernamePublicRestriction

Register

SC076491

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel